According to the findings by the World Gastroenterology Organisation, liver diseases have occupied 5th spot as the most common cause of death globally. Alone in the United States, it is the second leading cause of mortality amongst all digestive diseases. During the yesteryears, ailments related to the liver have carved a dominant spot in the list of chronic diseases and has eventually augmented the market for treatment. The widespread acceptance of non-vegetarian diet amalgamated with rapidly escalating consumption of alcohol and smoking tobacco are considered as prime causes of chronic liver diseases. Cholangitis is one such bacterial infection that causes inflammation in the bile duct, and its acute form can even lead towards the necessity of liver transplant. Another factor taking forward the cholangitis market demand globally is the trend of ‘fast food’ is widely established, leading towards conditions such as high cholesterol, obesity, and non-alcoholic fatty liver disease. According to the Centers for Disease Control and Prevention, by 2016, one of three Americans (36%) consumed a meal at fast-food eateries on any given day. Moreover, the increasing population accepting non-vegetarian diet can be indicated by the fact that the animal farming sector is responsible for 40% of the global agricultural production value. 

Similar escalation is witnessed in alcohol consumption rates, as WHO stated that 2.3 (approximately 30%) billion people in 2018 were alcohol consumers. Per capita consumption has grown from 5.5 liters of pure alcohol in 2005 to 6.4 liters in 2016. As health consequences, harmful use of alcohol resulted in some 3 million deaths, and 21.3% of such deaths were attributed to digestive diseases. Hence, changing lifestyle and dietary habits have further augmented the chances of cholangitis in individuals that are leading towards innovations in the market of its treatment. For example, FDA in 2019 granted Breakthrough Therapy Designation to seladelpar for the treatment of early-stage primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA). As PBC is a chronic form of cholangitis with a substantial share in the market, such approvals in its medication are adding further impetus to this segment. Similarly, in 2016, FDA had approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. The global cholangitis market size was evaluated to be $250 million in 2018. Moreover, with increasing geriatric population amalgamated with an increasing number of consumers of alcohol and meat that are more prone to chronic liver diseases, opportunities in the market are progressing with a global CAGR of 4.8% during the forecast period of 2019-2025.

Global Cholangitis Market –Types of Treatment and Diagnosis:

The global cholangitis market by type is bifurcated into primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), secondary cholangitis, and immune cholangitis. Broader segmentation includes chronic cholangitis and acute cholangitis, whereas the former happens slowly over time and can cause symptoms over 5 to 20 years, the later happens suddenly and can cause symptoms over a short period. As acute cholangitis is sudden, it often fails to respond to treatments in the form of drugs. Hence other expensive procedures are implemented to treat the condition derived from it, such as gallstones. It also requires gall bladder treatment process such as Cholecystectomy (surgical removal of the gallbladder). A severe form of acute cholangitis can also lead to multiple organ failure and require a transplant. The treatment process involved is endoscopy, percutaneous transhepatic cholangiogram (PTC), and cholecystectomy. Moreover, several forms of diagnosis are blood tests, imaging tests (Ultrasound, CT Scan, MRI), and liver biopsy. As a consequence of its abrupt incidence involving several forms of treatment and diagnosis processes, acute cholangitis is the fastest-growing type progressing with a CAGR of 3.5% going through up to 2025.

13,111 candidates in the U.S. waiting for liver to be donated for transplantation; pancreatic cancer results in 7% of all cancer deaths:

In terms of regional markets for the treatment of various forms of cholangitis, North America is reckoned to be the most lucrative marketplace. As stated earlier, liver diseases are the second leading cause of mortality amongst all digestive diseases in the U.S. Moreover, Organ Procurement and Transplantation Network under the U.S Department of Health and Services states that out of 113,180 candidates waiting for organ donation 13,111 cases are directly relevant to the liver. Apart from prevailing medical conditions, dietary habits influenced by the trend of ‘fast-food’ is adding further impetus to cholangitis market in North America. The increasing level of alcohol and meat consumption can also never be underrated as a factor impacting the epidemic of cholangitis in this region.

Another pivotal factor directly influencing the market in North America is increasing incidences of pancreatic cancer in this region, as individuals with this type of cancer are more prone towards developing the condition of cholangitis. According to the American Society of Clinical Oncology (ASCO), it is estimated that 56,770 adults in the United States will be diagnosed with pancreatic cancer representing approximately 3% of all cancers. Pancreatic cancer is the fourth leading cause of cancer-related deaths and accounts for 7% of overall cancer deaths in the United States. Hence, the increasing cases of pancreatic cancer in the U.S is a major factor driving North American cholangitis market growth.

Cholangitis Market Companies:

Some of the key players operating in the global cholangitis market are Gilead Sciences, Inc, Riemser Arzneimittel AG, Bayer AG, Zambon Company S.p.A., Taiho Pharmaceutical Co., Ltd., and Mayo Clinic.

As Primary sclerosing cholangitis (PSC) represents a foremost unmet medical need, several market players are involved in clinical trials of medicines to leverage the untapped medicine market for cholangitis. For example, Gilead Sciences, Inc, are at phase 3 of a clinical trial for Cilofexor (FXR agonist) that is a nonsteroidal farnesoid X receptor agonist that is supportive during the treatment of PSC.

Talk to one of our sales representative about the full report by providing your details in the link below:


Related Reports:

A. Primary Biliary Cirrhosis (Pbc) Treatment Market

B. Liver Transplantation Market


Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

To request for a proposal, provide your details in the below link:


Media Contact:

Mr. Venkat Reddy

Sales Manager

Email : [email protected]

Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.